From: Management of Influenza Symptoms in Healthy ChildrenCost-effectiveness of Rapid Testing and Antiviral
Therapy
Arch Pediatr Adolesc Med. 2005;159(11):1055-1062. doi:10.1001/archpedi.159.11.1055
Figure Legend:
Decision model for treating influenzalike illness in children. Decision node (square), chance events (circles), and terminal nodes
(diamonds) are shown. The actual model contains separate antiviral branches for amantadine hydrochloride and oseltamivir
phosphate, and separate rapid testing branches for the 2 rapid tests evaluated. ED indicates emergency department.
Date of download: 7/28/2017
Copyright © 2005 American Medical
Association. All rights reserved.
From: Management of Influenza Symptoms in Healthy ChildrenCost-effectiveness of Rapid Testing and Antiviral
Therapy
Arch Pediatr Adolesc Med. 2005;159(11):1055-1062. doi:10.1001/archpedi.159.11.1055
Figure Legend:
Incremental cost-effectiveness of oseltamivir phosphate depending on the proportion of influenza that is type B. Costs and
effectiveness are relative to empirical amantadine hydrochloride therapy. Ratios greater than $100 000 per quality-adjusted life-year
(QALY) are generally considered expensive while those less than $50 000 per QALY are considered attractive.
Date of download: 7/28/2017
Copyright © 2005 American Medical
Association. All rights reserved.
From: Management of Influenza Symptoms in Healthy ChildrenCost-effectiveness of Rapid Testing and Antiviral
Therapy
Arch Pediatr Adolesc Med. 2005;159(11):1055-1062. doi:10.1001/archpedi.159.11.1055
Figure Legend:
Monte Carlo probabilistic sensitivity analysis for a 15-year-old with influenza illness during a local epidemic in a mixed influenza A
and B season. Each line shows the proportion of simulations in which a particular strategy would be favored for willingness-to-pay
values per quality-adjusted life-year (QALY) saved.
Date of download: 7/28/2017
Copyright © 2005 American Medical
Association. All rights reserved.